Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Imricor Medical Systems's enterprise value is A$598.79 Mil.
Imricor Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-38.50 Mil. Therefore, Imricor Medical Systems's EV-to-EBITDA for today is -15.55.
The historical rank and industry rank for Imricor Medical Systems's EV-to-EBITDA or its related term are showing as below:
ASX:IMR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.55 Med: -4.77 Max: 0.32
Current: -15.55
During the past 8 years, the highest EV-to-EBITDA of Imricor Medical Systems was 0.32. The lowest was -17.55. And the median was -4.77.
ASX:IMR's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.005
vs ASX:IMR: -15.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Imricor Medical Systems (ASX:IMR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Imricor Medical Systems's PE Ratio (TTM) for today is calculated as:
Imricor Medical Systems's share price for today is A$1.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imricor Medical Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.122.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's EV-to-EBITDA falls into.
Imricor Medical Systems's current Enterprise Value is A$598.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imricor Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-38.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a EV-to-EBITDA of -15.55 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Imricor Medical Systems. According to the industry distribution chart, Imricor Medical Systems ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Imricor Medical Systems' EV-to-EBITDA too high?
Imricor Medical Systems' current EV-to-EBITDA is -15.55. Based on the distribution chart, Imricor Medical Systems ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #999999 out of 510 companies for EV-to-EBITDA. This places Imricor Medical Systems in the lower half of its industry. The industry median EV-to-EBITDA is 14.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.01, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Imricor Medical Systems. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current EV-to-EBITDA is -15.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.73 — trading 1630% above its estimated fair value. The current EV-to-EBITDA is -15.55. Imricor Medical Systems' overall GF Score™ is 42/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current EV-to-EBITDA is -15.55 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.73 is trading 1630% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
EV-to-EBITDA: -15.55
GF Value™: A$0.10 vs. price of A$1.73 (1630% above fair value)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
42GF Score
Get the complete analysis for ASX:IMR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
